FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
2.290
-0.110 (-4.58%)
At close: Dec 11, 2024, 4:00 PM
2.330
+0.040 (1.75%)
After-hours: Dec 11, 2024, 4:16 PM EST
FibroBiologics Employees
FibroBiologics had 10 employees as of December 31, 2023. The number of employees increased by 3 or 42.86% compared to the previous year.
Employees
10
Change (1Y)
3
Growth (1Y)
42.86%
Revenue / Employee
n/a
Profits / Employee
-$1,777,900
Market Cap
79.37M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | 3 | 42.86% |
Dec 31, 2022 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
EDAP TMS | 307 |
908 Devices | 230 |
PMV Pharmaceuticals | 63 |
Werewolf Therapeutics | 47 |
Ovid Therapeutics | 40 |
HeartBeam | 15 |
CervoMed | 8 |
FBLG News
- 22 days ago - FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly - GlobeNewsWire
- 27 days ago - FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics - GlobeNewsWire
- 4 weeks ago - FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - GlobeNewsWire
- 6 weeks ago - FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 - GlobeNewsWire
- 7 weeks ago - FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - GlobeNewsWire
- 2 months ago - FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office - GlobeNewsWire
- 2 months ago - FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire